NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
NeoImmuneTech
NeoImmuneTech
Hoffmann-La Roche
EMD Serono
Boehringer Ingelheim
Eli Lilly and Company
EMD Serono
Tesaro, Inc.
AstraZeneca
AstraZeneca
Pfizer
Boehringer Ingelheim
University of Kentucky
AbbVie
Pfizer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Palleon Pharmaceuticals, Inc.
Trishula Therapeutics, Inc.
Trishula Therapeutics, Inc.
Abramson Cancer Center at Penn Medicine
GlaxoSmithKline
Hoffmann-La Roche
Pfizer
Numab Therapeutics AG
Spanish Lung Cancer Group
Intensity Therapeutics, Inc.
Merck Sharp & Dohme LLC
Celgene
MedImmune LLC
Celgene
Case Comprehensive Cancer Center
GlaxoSmithKline
National Cancer Institute (NCI)
University of California, San Diego
Helsinn Healthcare SA
Helsinn Healthcare SA
Pfizer
Helix BioPharma Corporation
Advaxis, Inc.
Exelixis
Pfizer
Puma Biotechnology, Inc.
GlaxoSmithKline
Massachusetts General Hospital
AstraZeneca
Pfizer
CytomX Therapeutics
Apexigen America, Inc.
Sumitomo Pharma America, Inc.
RefleXion Medical
Weill Medical College of Cornell University